U.S. Markets open in 4 hrs 47 mins

Annovis Bio, Inc. (ANVS)

NYSE - NYSE Delayed Price. Currency in USD
18.80+0.33 (+1.79%)
At close: 04:00PM EDT
18.80 0.00 (0.00%)
After hours: 05:00PM EDT

Annovis Bio, Inc.

1055 Westlakes Drive
Suite 300
Berwyn, PA 19312
United States
610 727 3913

Full Time Employees3

Key Executives

NameTitlePayExercisedYear Born
Dr. Maria L. Maccecchini Ph.D.Founder, CEO, Pres & Exec. Director791.6kN/A1951
Mr. Henry Hagopian III, M.B.A.Chief Financial OfficerN/AN/A1968
Dr. Cheng Fang Ph.D.Sr. VP of R&DN/AN/AN/A
Ms. Eve M. Damiano M.S., RACSr. VP of Regulatory OperationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Corporate Governance

Annovis Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.